Goldman Sachs Downgrades BioMarin's Target Price to $104.00

Summary

Goldman Sachs has lowered the target stock price for Biomarin Pharmaceutical (NASDAQ: BMRN) from $124.00 to $104.00 while maintaining a ‘buy’ rating. This adjustment suggests a potential 66.81% upside relative to the previous day’s closing price. Other analysts have mixed ratings and target prices, averaging a ‘moderate buy’ with an average target price of $93.45. Biomarin’s stock is trading at $62.35, with a market capitalization of $11.9 billion, and recent earnings reports have shown positive results. Market Beat

Impact Analysis

The event is classified at the company level, as it pertains specifically to Biomarin Pharmaceutical. The downgrade of the target price by Goldman Sachs suggests changes in the valuation and market expectations for Biomarin. First-order effects include immediate investor reactions, potentially leading to volatility in Biomarin’s stock price. Other analysts provide mixed ratings, indicating uncertainty and varying perspectives on Biomarin’s future performance. Second-order effects might involve shifts in investor sentiment towards biotechnology companies similar to Biomarin, influencing sector-wide moves. Investment opportunities include evaluating Biomarin’s stock for potential entry points given its ‘buy’ rating from Goldman Sachs, despite the lowered target price. Risks involve potential further downgrades or negative news impacting future valuations. Market Beat